8-K - Forte Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Forte Biosciences reported a full year 2025 net loss of $69.4 million, driven by increased R&D spending for FB102 clinical trials, ending the year with $77.0 million in cash.

Key Takeaways

1R&D expenses increased to $58.2 million in 2025 from $21.2 million in 2024, primarily driven by $36 million in FB102 manufacturing and clinical costs.

2Net loss widened to $69.4 million for 2025 compared to $35.5 million in 2024, resulting in a basic and diluted net loss per share of $4.71.

3Cash and cash equivalents totaled $77.0 million as of December 31, 2025, up significantly from $22.2 million at the end of 2024.

4G&A expenses decreased to $12.4 million in 2025 from $15.4 million in 2024, largely due to lower litigation and settlement expenses.

5FB102 Phase 2 celiac disease topline results and Phase 1b vitiligo results are expected in 2026.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

Financial Results

9.01

. | Financial Statements and Exhibits. | |---|---| (d) Exhibits Exhibit: 99.1 | Description: Press Release dated March 31, 2026 Exhibit: 104 | Description: Cove

Exhibits Only

Source Document

Results of Operations

Fiscal Year 2025

Metric	Value	Basis	Prior Period
Research and Development Expenses	$58.20	GAAP	$21.20
General and Administrative Expenses	$12.40	GAAP	$15.40
Net Loss	$-69.38	GAAP	$-35.48
Net Loss Per Share - Basic and Diluted	$-4.71	GAAP	$-12.17
Loss from Operations	$-70.66	GAAP	$-36.60
Interest Income	$2.72	GAAP	$1.31

Exhibits (2)

8-K

99.1

EX-99.1